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Summary
Sjo¨gren-Larsson syndrome (SLS) is an autosomal re-
cessive disorder characterized by ichthyosis, mental
retardation, spasticity, and deficient activity of fatty
aldehyde dehydrogenase (FALDH). To define the mo-
lecular defects causing SLS, we performed mutation
analysis of the FALDH gene in probands from 63 kin-
dreds with SLS. Among these patients, 49 different
mutations—including 10 deletions, 2 insertions, 22
amino acid substitutions, 3 nonsense mutations, 9
splice-site defects, and 3 complex mutations—were
found. All of the patients with SLS were found to
carry mutations. Nineteen of the missense mutations
resulted in a severe reduction of FALDH enzyme cat-
alytic activity when expressed in mammalian cells, but
one mutation (798GrC [K266N]) seemed to have a
greater effect on mRNA stability. The splice-site mu-
tations led to exon skipping or utilization of cryptic
acceptor-splice sites. Thirty-seven mutations were pri-
vate, and 12 mutations were seen in two or more
probands of European or Middle Eastern descent.
Four single-nucleotide polymorphisms (SNPs) were
found in the FALDH gene. At least four of the com-
mon mutations (551CrT, 682CrT, 733GrA, and
798+1delG) were associated with multiple SNP hap-
lotypes, suggesting that these mutations originated in-
dependently on more than one occasion or were an-
cient SLS genes that had undergone intragenic
recombination. Our results demonstrate that SLS is
caused by a strikingly heterogeneous group of mu-
tations in the FALDH gene and provide a framework
for understanding the genetic basis of SLS and the
development of DNA-based diagnostic tests.
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Introduction
Sjo¨gren-Larsson syndrome (SLS [MIM 270200]) is an
autosomal recessive disease characterized by ichthyosis,
mental retardation, and spastic diplegia or tetraplegia
(Sjo¨gren and Larsson 1957; Rizzo, in press). Ichthyosis
is usually apparent at birth and has a generalized dis-
tribution. The neurological symptoms appear during the
1st or 2d year of life and result in delay in achievement
of motor and cognitive milestones. Spastic diplegia pre-
vents or impedes walking in most patients with SLS.
Seizures occur in ∼40% of patients. Retinal abnormal-
ities, such as glistening white dots in the perimacular
region and pigmentary changes, are often seen in patients
with SLS, and photophobia is a common complaint (Ja-
gell et al. 1980). Many patients have short stature as a
result of growth delay and leg contractures (Jagell and
Heijbel 1982).
Patients with SLS have deficient activity of fatty al-
dehyde dehydrogenase (FALDH) (E.C. 1.2.1.48; Enzyme
Nomenclature Database) (Rizzo and Craft 1991), a mi-
crosomal nicotinamide-adenine-dinucleotide (NAD)–de-
pendent enzyme that is necessary for the oxidation of
long-chain aliphatic aldehydes to fatty acids (Kelson et
al. 1997). Because FALDH is a component of the fatty
alcohol:NAD oxidoreductase (FAO) complex, which
catalyzes the oxidation of fatty alcohol, patients with
SLS show deficient activity of both FALDH and FAO
(Rizzo et al. 1988). Measurement of either enzyme pro-
vides a specific diagnostic test for this disease. Tissue
accumulation of fatty alcohol, fatty aldehyde, and re-
lated lipid metabolites is thought to be responsible for
the symptoms, but the pathogenic mechanisms are un-
clear (Rizzo, in press).
SLS is caused by mutations in the FALDH gene on
chromosome 17p11.2 (De Laurenzi et al. 1996). The
FALDH gene (also called “ALDH10”) consists of 11
exons and is widely expressed in tissues (Chang and
Yoshida 1997; Rogers et al. 1997). The major FALDH
transcript in all tissues examined is composed of 10 ex-
ons and encodes a protein of 485 amino acids. Alter-
native splicing of the gene results in a minor transcript
that includes an additional sequence (exon 9′) that gives
rise to a larger protein of 508 amino acids with a variant
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Figure 1 Large deletion mutation (1535r386–408delins19bp) in a homozygous SLS patient. A, PCR amplification of a fragment of
the FALDH gene spanning exons 1–3 in a normal control patient, in the mother of the patient, and in the homozygous SLS patient (SLS). MW
= molecular-weight markers. The normal PCR product is 3.5 kb, whereas the product of the deletion mutation is 0.7 kb. B, Illustration of the
normal and deleted FALDH gene. C, DNA sequences at the deletion breakpoints. A duplicated portion of intron 2 has been inserted and is
underlined with a dotted line. Nucleotides flanking the deletion/insertion are numbered according to the FALDH cDNA nomenclature.
carboxy-terminal sequence (Rogers et al. 1997). The car-
boxy-terminal domain of the more abundant FALDH
protein is necessary for anchoring of the enzyme to the
microsomal membrane (Masaki et al. 1994), but the
function of the minor protein isoform is as yet unknown.
In addition, utilization of three distinct polyadenylation
sites gives rise to transcripts that differ in length (2.0,
4.0, and 4.2 kb).
Several mutations in the FALDH gene have been re-
ported in patients with SLS (De Laurenzi et al. 1996,
1997; Rizzo et al. 1997; Sille´n et al. 1997, 1998; Tsu-
kamoto et al. 1997; Willemsen et al. 1999). Two mu-
tations (943CrT and 1297–1298delGA) are common
among European patients (De Laurenzi et al. 1997;
Rizzo et al. 1997; Sille´n et al. 1997). However, the spec-
trum of mutations that can cause SLS has not yet been
well defined, especially among patients of non-European
origin, and only one mutation (943CrT) has been ex-
pressed to confirm that it actually destroys enzymatic
activity. We therefore performed mutation analysis of 63
probands with SLS, representing kindreds from through-
out the world. Our results demonstrate a striking mu-
tational heterogeneity in SLS and provide insight into
the nature and origin of the molecular defects causing
this disease.
Material and Methods
Patients with SLS and Control Subjects
Probands with SLS, from 63 kindreds, were studied.
None of the probands were known to be genetically
related. All patients with SLS were confirmed to have
FALDH deficiency in cultured skin fibroblasts (Rizzo
and Craft 1991). A control population consisted of 66
normal subjects (51 Europeans, 7 African Americans, 4
American Indians, 3 Asians, and 1 individual from the
Middle East). This research was approved by the Com-
mittee on the Conduct of Human Research at the Med-
ical College of Virginia.
Cells
Cultured skin fibroblasts were grown in Dulbecco’s
minimal essential medium containing 10% fetal bovine
serum, penicillin, and streptomycin, at 37C in an at-
mosphere of 5% CO2. Chinese hamster ovary cells de-
ficient in FALDH (FAA-K1A) were kindly provided by
Dr. R. A. Zoeller, Boston University School of Medicine
(James and Zoeller 1997), and were grown in F12 me-
dium containing 5% fetal bovine serum.
DNA Isolation
Genomic DNA was purified from blood or cultured
fibroblasts, by means of the Wizard Genomic DNA Pu-
rification Kit (Promega). Alternately, DNA used for PCR
was obtained from buccal brushings or fibroblast pellets,
as described elsewhere (Richards et al. 1993).
FALDH Assay
Cultured skin fibroblasts were harvested by trypsini-
zation, and FALDH was assayed with octadecanal as
substrate (Rizzo and Craft 1991; Kelson et al. 1997). In
experiments measuring expression of mutant FALDH,
transfected Chinese hamster ovary cells were homoge-
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Table 1
Oligonucleotide Primers Used to Amplify Exons in the FALDH Gene from Genomic DNA
Exon or Intron and Primera Sequence
Exon 1:
HF21S (forward) 5′-CCTGGGCGAGTGAATTGTGGCT-3′
HF20Ai (reverse) 5′-TCTGTATCGCTGGAGATCATACTC-3′
Exon 2:
HF15Si (forward) 5′-CAGTTGTTGTCACTACAGGTGTACCTG-3′
INT 2 (reverse) 5′-GGTGTAAACAAAGGCAAATCACC-3′
Exon 3:
INT 2 (forward) 5′-GAGCTGCAGAAATAATTGGGAGTACCTAGC-3′
INT 3/2 (reverse) 5′-GAACTTCTTTTGCTAAGCCAACTGTTGAAG-3′
Exon 4:
HF14Si (forward) 5′-TATTTGGCAGTGCAAGAGTTTGT-3′
HF14Ai (reverse) 5′-ACAAAAGAGTAACACTGTCAGGAAAAGTC-3′
Exon 5:
HF18Si (forward) 5′-ATTATATAGCTGTTCTGGATGTTTTC -3′
INT 5/1 (reverse) 5′-GGGAGAAACAAATGGGGATGCTGC-3′
Exon 6:
HF16Si (forward) 5′-GCATGGCTGGATTTTGTACTTACTG-3′
INT 6 (reverse) 5′-GTGGCGTCATTCAATACACAGAAAC-3′
Exon 7:
HF13Si (forward) 5′-GCACAGTTCATCCACGTGCTCAG-3′
HF17Ai (reverse) 5′-GGAACATGACTCTTGACAGTTGCTTATG-3′
Exon 8:
INT 7 (forward) 5′-TTGACACATAACTGAGCACACAGCCCTC-3′
HF15Ai (reverse) 5′-AGCAGCCCATACAATCCACTCATGA-3′
Exon 9:
HF17Si (forward) 5′-CAGAAGTAGCTTGCATCATCTACAGTG-3′
HF16Ai (reverse) 5′-CTAGAATATGCATCTGGCAGCCATC-3′
Exon 10:
INT 9/2 (forward) 5′-TGTACAATGCATGTAGAGTCTCTTCAG-3′
FALDH 3′ (reverse) 5′-GGCAATGACTTTTAAGTTTGATCACAGAGTGTTTG-3′
Exon 9′:
HF19Si (forward) 5′-TGGGCAATAGAGCGAGACTCCATC-3′
HF19Ai (reverse) 5′-CCACTTGGCCCACCTTACATATAG-3′
Intron 1 SNP:
HK8 (forward) 5′-GAGGCCCTGCGGAGGATGGTGCA-3′
C153(39) (reverse) 5′-GTCCACAAGTGCGCGTCGG-3′
T153(39) (reverse) 5′-GTCCACAAGTGCGCGTCGA-3′
Exon 10 SNP:
INT 9/2 (forward) 5′-TGTACAATGCATGTAGAGTCTCTTCAG-3′
A1446 (reverse) 5′-CAGGATCATTCTTCAGTAATACTCT-3′
T1446 (reverse) 5′-CAGGATCATTCTTCAGTAATACTCA-3′
a Primers were generated from flanking intron (Rogers et al. 1997) or exon (De Laurenzi
et al. 1996) sequences (GenBank). Primers used to detect SNPs incorporated nucleotide mis-
matches (underlined) to improve allele specificity.
nized in buffer containing 0.1% Triton X-100 and 0.1
mM phenylmethylsulfonyl fluoride, rather than in the
usual homogenization buffer (Rizzo and Craft 1991).
Mutation Analysis
The FALDH gene was screened for mutations by use
of direct DNA sequencing of PCR-amplified exons.
FALDH exons (GenBank) were amplified from genomic
DNA, with use of the primer pairs shown in table 1. All
reactions were performed in 50 ml final volume with 1
U Taq polymerase (PE Biosystems), 2.5 mM MgCl2, 0.5
mM each dNTP, 5 pmol each oligonucleotide primer,
and a variable amount of purified DNA or buccal-brush-
ing DNA. Reactions were initiated by hot start with
addition of the Taq polymerase. The thermocycling con-
ditions used for amplification of exons 2–10 consisted
of an initial denaturation at 94C for 5 min; then 35
cycles of denaturation at 94C for 30 s, annealing at 62
for 30 s, and extension at 72C for 1 min; and then a
final extension at 72C for 5 min. The coding sequence
of exon 1 was amplified as described above, with the
use of denaturation steps at 96C and an annealing tem-
perature of 65C. PCR products were sequenced by use
of the BigDye Terminator Cycle Sequencing Kit (PE Bios-
ystems), with the same primers that were used for exon
amplification, and the products were then analyzed on
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Figure 2 Aberrant splicing caused by three splice-donor muta-
tions at the junction of exon 5 and intron 5. A, Normal and mutant
DNA sequences. Exon sequence is indicated by uppercase letters, in-
tron sequence by lowercase letters. B, Amplification of fibroblast
FALDH mRNA by RT-PCR shows that all three mutations result in
two abnormal transcripts, one of which skips exon 5 and the other
of which skips exons 4 and 5.
an ABI 377A sequencer. All mutations were confirmed
by sequencing the exons with both sense and antisense
primers and by digestion with restriction enzymes when-
ever mutations altered a restriction site. In some complex
mutations and in certain compound heterozygotes, PCR
products were cloned into plasmid pNoTA/T7 (Prime
PCR Cloner System; 5 Primer3 Prime, Inc.) prior to the
sequencing.
Amplification of DNA fragments 12 kb (shown in fig.
1) was performed by use of the Expand Long Template
PCR System (Roche), according to the manufacturer’s
instructions. The forward primer was HK8, and the
reverse primer was Int 3/2 (table 1). Thermocycling
conditions consisted of an initial denaturation at 94C
for 2 min, then 5 cycles of denaturation at 94C for 10
s and annealing/extension at 68C for 2 min, and then
30 subsequent cycles at 94C for 10 s and at 68C for
2.5 min with increments of 20 s/cycle. Mutations were
described according to the nomenclature of Antonarakis
(1998) and are identified by the cDNA nucleotide–num-
bering system.
Analysis of Splice-Site Mutations
To identify the aberrant transcripts resulting from
splice-site mutations, total RNA was isolated from cul-
tured fibroblasts by use of the SV Total RNA Isolation
System (Promega), and it was amplified by reverse-tran-
scription–PCR (RT-PCR) (Access RT-PCR System; Pro-
mega) by use of exonic primers, as described elsewhere
(De Laurenzi et al. 1996). DNA products were separated
by agarose electrophoresis, were isolated, and then were
either sequenced directly or cloned prior to being se-
quenced.
To amplify the aberrant FALDH transcripts arising
from donor splice-site mutations in exon 5 (shown in
fig. 2), the following primers were used for RT-PCR:
(forward) 5′-ATCTTGGCAAAGCTTCTCCCTCAGT
ATTTAGACC-3′ and (reverse) 5′-GGCCTCATCAG
TCTCCCCACCAAAAGCTATC-3′. To amplify the
FALDH mRNA shown in figure 3, we used the fol-
lowing primers: (forward) 5′-CTGCTGCCAAGC
ATCTGACCCCTGTGAC-3′ and (reverse) 5′-AGG-
TTTGGCCACAATTCATGTATTTTCCCCAGG-3′.
The cDNA synthesis reaction occurred at 48C for 45
min, with the use of 200 ng RNA. After initial de-
naturation at 94C for 2 min, PCR consisted of 5
cycles of denaturation at 94C for 0.5 min and an-
nealing/extension at 68C for 2 min, and then 30 cy-
cles of denaturation at 94C for 0.5 min, annealing
at 64C for 1 min, and extension at 68C for 2 min.
A final extension time was 5 min at 68C.
Mammalian Expression of FALDH Mutations
To express FALDH mutations, we constructed an ex-
pression vector containing an S-tag attached to the 5′
end of the FALDH cDNA, by cloning the FALDH cDNA
into an S-tag plasmid (Novagen) and by subcloning the
S-tag-FALDH construct into the pCIneo (Promega)
mammalian expression vector. Mutations were intro-
duced into the S-FALDH-pCIneo expression vector by
means of site-directed mutagenesis performed with the
use of the Transformer Site-Directed Mutagenesis Kit
(Clontech), and they were confirmed by DNA sequenc-
ing. Plasmid DNA was purified and transfected into
FAA-K1A cells with the use of Fugene-6 reagent (Roche),
according to the manufacturer’s instructions. FALDH
activity in the cells was measured after 2 d. To confirm
that loss of enzyme activity did not arise simply from
inefficient expression of the mutant FALDH, the con-
centration of S-Tag protein was measured with the S-
Tag Rapid Assay Kit (Novagen), in the same cell homo-
genates used for FALDH assay. FALDH activity was nor-
malized to S-tag protein, and the enzyme-specific activity
measured in cells transfected with the mutant construct
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Figure 3 Splice-acceptor–site mutation 681–14TrA and its effect on FALDH mRNA and protein. A, RT-PCR products, obtained with
the use of primers in exons 4 and 5, separated in a 10% polyacrylamide gel. The left lane shows normal RNA, and the right lane shows patient
RNA demonstrating an abnormal larger product arising from a 24-bp insertion in the patient’s mRNA. B, Mutation and sequence of the
abnormally spliced larger transcript. The larger product was amplified from an aberrant FALDH transcript that arose from utilization of a
cryptic splice-acceptor site upstream of the mutation, whereas the smaller product represents the normally spliced transcript. Normal and cryptic
splice-acceptor sites are underlined. The mutation is denoted by a boxed letter “a.”
was expressed as a percentage of the activity measured
with the wild-type cDNA vector.
Polymorphism Screening
Two single-nucleotide polymorphisms (SNPs) in the
gene altered restriction-enzyme cut sites. To screen for
the intron 3 polymorphism at 47131T/C, a 342-bp
genomic DNA fragment was amplified by PCR, with
the use of exon 3 primers (table 1), and the DNA (0.5
mg) was digested overnight with 20 U NdeI in a 25-
ml reaction volume, according to the manufacturer’s
instructions. The 47131T allele was cut with NdeI,
producing 224-bp and 118-bp products, whereas
NdeI did not cut the alternate C allele. In a similar
fashion, a 422-bp fragment containing the intron 6
polymorphism (94053G/C) was amplified with pri-
mers for exon 6 (table 1) and was digested with 10
U HphI. The 94053G allele was cut by HphI, gen-
erating 281-bp and 141-bp products, whereas
94053C was not cut. For both polymorphisms,
DNA from control individuals who were homozygous
or heterozygous for the polymorphic variants was si-
multaneously treated, to verify complete digestion.
The digestion products were separated on a 2% aga-
rose gel and were stained with ethidium bromide.
Two other polymorphisms, 1446A/T in exon 10 and
15339C/T in intron 1, were detected by means of
allele-specific PCR. As an internal control, multiplex
PCR was performed by coamplification of exon 6. The
PCR contained 1 U Taq polymerase, 2.5 mM MgCl2,
0.5 mM each dNTP, 2 pmol each exon 6 primer (table
1), buccal or fibroblast DNA, and polymorphism-spe-
cific primers, in a final volume of 50 ml. To selectively
coamplify the 1446A allele, the PCR also contained
5 pmol forward primer for exon 10 (table 1, primer
Int 9/2) and 10 pmol A1446 allele-specific reverse
primer (table 1). The cycling conditions were the same
as those described above for amplification of exons
2–10. To selectively amplify the 1446T allele, the
A1446 primer was replaced with 10 pmol antisense
T1446 primer, and an annealing temperature of 63C
was used. To screen for the 15339C/T polymor-
phism in intron 1, the PCR mixture was modified from
that described above, in that it contained 1 pmol each
exon 6 primer, 15 pmol exon 1 forward primer (table
1), and 15 pmol reverse primer C153(39) or
T153(39) (table 1). The cycling conditions were as
follows: annealing temperatures of 60C for the C al-
lele and 62C for the T allele. PCR products were
separated on either a 1.5% or 2% agarose gel and
were visualized with ethidium bromide. There was
complete concordance between results of DNA se-
quencing and those for allele-specific PCR screening
for the intron 1 (n=37) and exon 10 ( ) poly-n = 24
morphisms.
Results
Among 63 probands with SLS, we detected 49 dif-
ferent mutations, including 10 deletions, 2 insertions, 22
amino acid substitutions, 3 nonsense mutations, 9 splice-
site mutations, and 3 complex mutations (table 2). All
Table 2
Mutations Detected in Probands with SLS
Type of Mutation
and Exon Nucleotide Changea Protein or Transcript Change
No. of Probands with Mutation
(Ethnic or Geographic Origin)
Deletion:
2 1535r386–408delins19bp Delete exon 2 and frameshiftrtruncation 1 (Turkishb)
2 286–296del Frameshiftrtruncation 1 (Middle Easternb)
2 338delA Frameshiftrtruncation 1 (Spanish)
2 374–378del Frameshiftrtruncation 1 (Middle Eastern)
3 469delC Frameshiftrtruncation 1 (Polish, Swiss)
6 821–822delAA Frameshiftrtruncation 1 (European)
7 968delC Frameshiftrtruncation 1 (Turkish)
7 1100delA Frameshiftrtruncation 1 (English, Irish, Polish, American Indian)
9 1291–1292delAA Frameshiftrtruncation 1 (Japaneseb)
9 1297–1298delGA Frameshiftrtruncation 16 (Europeanb)
Insertion:
4 620–621insG Frameshiftrtruncation 1 (Italian)
9 1311–1312insACAAA Frameshiftrtruncation 1 (Frenchb)
1 (French, Irish, American Indian)
Complex:
56 [733GrA, 901GrC, 906delT, 909TrG] D245N, A301P, frameshiftrprotein truncation 4 (Europeanb)
7 941–943delCCCins21bp A314Ginsert 6 amino acidsP315A 2 (Lebaneseb)
1 (Greekb)
1 (Middle Eastern, European)
8 1108–1116delins ACAG Frameshiftrtruncation 1 (Italian)
Missense:
1 133ArT I45F 1 (German)
2 191TrA V64D 1 (African American)
2 317TrG L106V 1 (Middle Easternb)
2 341CrT P114L 1 (Turkishb)
2 362CrT P121L 1 (African American)
4 551CrG T184R 1 (Tunisianb)
4 551CrTc T184M 1 (German), 2 (Europeanb)
1 (European, Middle Eastern)
4 554GrC G185A 1 (French, Irish, American Indian)
5 682CrTc R228C 2 (Palestinianb), 2 (Middle Easternb)
5 710GrA C237Y 2 (Arab-Jewish, Syrian-Jewishb)
5 733GrAc D245N 1 (European)
5 798GrC K266N; unstable transcript 1 (German)
6 835TrA Y279N 1 (European)
7 943CrT P315S 8 (Northern European, Swedishb)
7 984GrC M328I 1 (Mixed Europeanb)
7 1094CrTc S365L 2 (Germanb)
1 (German, English, Scottish)
9 1216GrA G406R 1 (Pakistanib)
9 1231CrT H411Y 1 (Egyptianb)
9 1244GrA S415N 1 (Germanb)
9 1256TrC F419S 1 (Middle Easternb)
9 1268GrAc R423H 1 (Middle Eastern)
9 1339ArG K447E 1 (Japaneseb)
Nonsense:
1 24–25CCrTT R9Ter 1 (Turkish)
1 28CrT Q10Ter 1 (Spanish)
2 233GrA W78Ter 1 (Italianb), 1 (French)
Splice-site:
Exon 3/intron 3 junction 4711delG Skips exons 2 and 3rin-frame deletion of amino acids 52–157 1 (Italian), 1 (Polish, Swiss)
Exon 3/intron 3 junction 4712TrG Skips exons 2 and 3rin-frame deletion of amino acids 52–157 1 (Mixed European)
Intron 3/exon 4 junction 4722ArG Skips initial 33 bp in exon 4 and uses downstream cryptic
acceptor site in exon 4rdeletion of amino acids 158–168 1 (Austrian)
Intron 4/exon 5 junction 6812ArG Skips exon 5rframeshift and premature termination 1 (French)
Intron 4/exon 5 junction 681–14TrA Causes use of a new cryptic acceptor site in intron 4,
adding 24 bp between exons 4 and 5rinsertion of 8
amino acids between C226 and R227; skips exon
5rframeshift and premature termination 1 (German)
Exon 5/intron 5 junction 7985GrA Skips exon 5rframeshift and premature termination;
skips exons 4 and 5rdeletion of amino acids 158–266 1 (Lebaneseb)
Exon 5/intron 5 junction 7981delG Skips exon 5rframeshift and premature termination;
skips exons 4 and 5rdeletion of amino acids 158–266 1 (Europeanb), 1 (Japaneseb)
Exon 5/intron 5 junction 79817986delGTTTGT Skips exon 5rframeshift and premature termination;
skips exons 4 and 5rdeletion of amino acids 158–266 1 (Hispanicb)
Intron 7/exon 8 junction 11081GrC Skips exon 8rframeshift and premature termination;
skips exons 8–9rin-frame deletion of amino acids
370–481 1 (Brazilianb)
a Mutation numbers refer to the cDNA position.
b Denotes mutations carried in a homozygous state by one or more probands.
c Transition mutation at CpG dinucleotide.
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Figure 4 Location of mutations within the FALDH cDNA. The major FALDH cDNA containing exons 1–10 is shown. Exon 9′, which
is spliced between exons 9 and 10 in a minor FALDH transcript, contains no mutations and is not illustrated. Arrows indicate mutation locations.
The numbers above some arrows refer to the number of different mutations located within several base pairs at the same location. An asterisk
(*) above an arrow indicates the beginning of the large deletion mutation encompassing intron 1 and extending through exon 2 and most of
intron 2. All splice-site mutations alter intron sequences.
of the probands carried FALDH mutations. Thirty
(48%) of the probands were homozygous for their mu-
tation. Thirty-seven of the mutations were each seen in
only one proband.
Exonic Deletions, Insertions, and Complex Mutations
Of the 10 deletions, 8 involved one or two nucleotides,
and 1 deletion consisted of 11 nucleotides (table 2). All
of these mutations cause a frameshift and a premature
stop codon. All four deletions that involved two or more
nucleotides were located at short palindromic sequences.
Two of the deletions in exon 9 (1291–1292delAA and
1297–1298delGA) involved the same 9-bp palindromic
sequence (AAGAGAGAA). With the exception of 1297–
1298delGA, which was found in 16 probands, all of
European origin, each deletion was carried by a single
proband. As shown in figure 4, the deletions were not
clustered in any region of the gene.
One large deletion was found in a homozygous state
in a consanguineous Turkish patient. Using PCR, we
amplified DNA across this deletion and generated a 0.7-
kb product in the patient and a 3.5-kb product in normal
control individuals (fig. 1A). Both PCR products were
generated with the use of DNA from the patient’s
mother. Sequencing the patient’s DNA fragment iden-
tified the deletion breakpoints beginning at nucleotides
(nt) 1535 in intron 1 and extending through nt
386–408 in intron 2 (fig. 1B and C). Interestingly, at the
break site, the patient also had a 19-bp insertion that
included a 10-bp duplication of normal intron 2 se-
quence. This mutation results in both deletion of exon
2 and, in exon 3, a frameshift associated with a pre-
mature stop codon.
Two small insertion mutations, each causing a frame-
shift, were found in our patients (table 2). The 1311–
1312insACAAA mutation is actually a small duplication
of a 5-bp sequence located immediately upstream of the
insertion site.
Three complex mutations involved a combination of
deletions, insertions, and nucleotide substitutions. One
of these (941–943delCCCins21bp) was seen in four
probands with Middle Eastern or Greek ancestry. This
mutation had previously been reported in a consan-
guineous patient of mixed European origin (De Laurenzi
et al. 1996), who was later discovered to have some
Lebanese ancestry. A second complex mutation involv-
ing a single nucleotide deletion and two transversions
(901GrC, 906delT, and 909TrG) in exon 6 was as-
sociated with 733GrA in exon 5 on the same allele.
This mutant allele was seen in four European probands,
including one who was homozygous for the allele. A
single Italian patient carried a third deletion/insertion
mutation (1108–1116delinsACAG) in exon 8.
Missense Mutations
Twenty-two missense mutations were detected (table
2). The amino acid substitutions were scattered across
the protein, but none involved the amino- or carboxy-
terminal 35 amino acids (fig. 4). Five of the missense
mutations were transitions that occurred at CpG dinu-
cleotides (table 2). Two different mutations (551CrG
and 551CrT) involved the same nucleotide and are pre-
dicted to cause substitution of Thr184 by Arg or Met,
respectively. Interestingly, the 733GrA mutation, which
was associated with a second complex mutation on the
same allele, was seen in combination with a second com-
plex mutation, was also found as an isolated homozy-
gous mutation in one proband.
To determine whether the missense mutations were
actually destructive to enzyme catalytic activity, we ex-
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Table 3
Expression of FALDH Missense Mutation in
Mammalian Cells
Mutation
Protein
Change
FALDH Activitya
(% of Wild Type)
Wild type None 100
133ArT I45F 9
191TrA V64D !1
317TrG L106V !1
341CrT P114L !1
362CrT P121L !1
551CrG T184R !1
551CrT T184M !1
554GrC G185A 1
682CrT R228C 9
710GrA C237Y !1
733GrA D245N 1
798GrC K266N 55
835TrA Y279N !1
943CrT P315S !1
984GrC M328I NT
1094CrT S365L 3
1216GrA G406R NT
1231CrT H411Y !1
1244GrA S415N !1
1256TrC F419S 3
1268GrA R423H 1
1339ArG K447E 1
NOTE.—Mutations were introduced into ex-
pression vector pCIneo-S-FALDH and were trans-
fected into FALDH-deficient Chinese hamster
ovary cells. Enzyme activity was measured after
48 h and was normalized to the amount of S-pro-
tein, to determine the specific activity. Each mu-
tation was expressed in two or three experiments,
and data shown are the mean percentage of the
mutant FALDH-specific activity compared with
wild-type enzyme.
a NT = not tested.
pressed 20 of these mutations in Chinese hamster ovary
cells that were genetically deficient in FALDH activity.
As shown in table 3, 19 of the mutant proteins had little
or no detectable FALDH activity, but the protein en-
coded by 798GrC (K266N) possessed considerable re-
sidual activity (55% of normal). As noted below, how-
ever, this mutation seemed to have a greater destructive
effect on mRNA stability than on enzyme catalytic
activity.
Splicing Mutations and Mutations That Cause Unstable
mRNA
Nine splice-site mutations were found (table 2).
Analysis of fibroblast FALDH mRNA showed that all
of these mutations resulted in an abnormal mRNA.
Five of the mutations altered splice-donor sites. Three
of these mutations (7985GrA, 7981delG, and
7981–7986delGTTTG) involved the splice-donor
site at the junction of exon 5 and intron 5 and were
carried by homozygous patients. As shown in figure
2, amplification of their fibroblast mRNA by RT-PCR
revealed two smaller aberrant transcripts that had de-
letions of exon 5 or of exons 4 and 5. Similarly, the
4711delG and 4712delT deletions at the splice-
donor site of exon 3 resulted in a shortened transcript
in which exons 2 and 3 were skipped.
In contrast to the splice-donor–site mutations, two
splice-acceptor–site mutations resulted in utilization of
cryptic acceptor sites. The 68114TrA mutation was
carried by a German patient who was a compound het-
erozygote for 1297–1298delGA in exon 9. RT-PCR am-
plification and sequencing of an mRNA fragment con-
taining exon 9 indicated that the GA deletion was not
represented, suggesting that this deletion transcript was
rapidly degraded (Maquat 1996). Amplification of the
mRNA across exons 3–6, which includes the region po-
tentially altered by the 68114TrA mutation, dem-
onstrated both an abnormally short product arising from
skipping of exon 5 and a product that appeared slightly
larger than the normal product (data not shown). When
the mRNA was amplified with primers in exons 4 and
5 that were closer to the mutation, two distinct prod-
ucts—one of normal size and one slightly larger—were
observed (fig. 3A). After cloning and sequencing of the
products, the more abundant longer transcript was
found to arise from aberrant recognition of a cryptic
acceptor site, located 24 bp upstream of exon 5, in intron
4 (fig. 3B). This cryptic acceptor site was not preceded
by the typical pyrimidine-rich region, and the mutation
itself generated a consensus AG that was not utilized as
an acceptor site. The mutant transcript results in an in-
frame insertion of eight amino acids in the FALDH pro-
tein, between Cys226 and Arg227.
The 4722ArG mutation altered the consensus AG
of the splice–acceptor site of exon 4. Analysis of the
mRNA showed utilization of the next available down-
stream AG as a cryptic acceptor site. This resulted in an
in-frame deletion of the first 33 nucleotides within exon
4 of the mRNA and a predicted loss of 11 amino acids
from the FALDH protein.
As noted above, expression of the 798GrC (K266N)
missense mutation resulted in an enzyme with 55% re-
sidual catalytic activity. Since this mutation altered the
last nucleotide in exon 5 and lowered the splice-donor
score from 80% to 67% (Shapiro and Senapathy 1987),
we wondered whether the transcript arising from this
allele might have altered splicing or mRNA instability.
A patient with SLS who was a compound heterozygote
for 943CrT in exon 7 carried the mutation. When the
patient’s FALDH mRNA was amplified by RT-PCR, the
943CrT mutation appeared to be homozygous and the
798GrC mutation could not be detected in the mRNA
(data not shown). No abnormally spliced transcripts
were seen. These results are compatible with decreased
stability of the mRNA arising from the 798GrC allele.
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Table 4
Allele Frequencies of SNPs in the FALDH Gene
Intron or Exon
and FALDH
Polymorphism
Normal Controls
(n = 132 chromosomes)
All SLS Probandsa
(n = 122 chromosomes)
SLS Probands
Carrying 1
Common Mutation
(n = 88 chromosomes)
SLS Probands
Carrying Private
Mutations Only
(n = 34 chromosomes)
Intron 1:
15339T .29 .55b .63b .35
15339C .71 .45b .37b .65
Intron 3:
47131C .27 .55b .63b .29
47131T .73 .45b .37b .71
Intron 6:
94053G .16 .22 .20 .26
94053C .84 .78 .80 .74
Exon 10:
1446A .51 .22b .16b .38
1446T .49 .78b .84b .62
a This group includes 61 probands carrying both common and private mutations. Two probands, including one patient who
carried a deletion lacking the intron 1 polymorphism, were not analyzed.
b Different from normal controls at level, by use of x2 analysis.P ! .05
Nonsense Mutations
Three nonsense mutations were found within exons
1 and 2. One of these was an unusual dinucleotide tran-
sition (24–25CCrTT) that involves codons 8 and 9 and
that causes no amino acid change in Val8 but that results
in a termination at codon 9.
Polymorphisms and Sequence Variants
During these studies we identified four SNPs within
the FALDH gene. Three SNPs were located within in-
tronic sequence (introns 1, 3, and 6), and one was a
previously reported silent polymorphism (1446A/T) that
involved the third nucleotide of the codon for Ala482
(Chang and Yoshida 1997; Sille´n et al 1998). The allele
frequencies of these SNPs were established in a popu-
lation of normal subjects and in the probands with SLS
(table 4). Interestingly, in the patients with SLS, the allele
frequencies of three SNPs differed from those in the nor-
mal population. This difference, however, probably re-
flected an overrepresentation of patients carrying com-
mon mutations, because the SNP-allele frequencies in a
subgroup of probands carrying only private mutations
appeared to be similar to those in the control pop-
ulation.
In addition to the SNPs, we detected a sequence
variation within intron 2, at 3866ArG, in two pa-
tients with SLS who carry the 1311–1312insACAAA
mutation. This nucleotide change was near the splice-
acceptor site at exon 3, but no splicing errors were
detected in the patients’ fibroblast mRNA. We con-
cluded that 3866ArG was an innocuous variation.
Patients with SLS Who Have Undetected or Uncertain
Mutations
In two compound-heterozygous patients, only one
of the two mutations could be detected after repeated
sequencing of the coding regions of all exons amplified
from genomic DNA. These patients, both of whom
were of European origin, carried the common
1297–1298delGA mutation on one allele. In both pa-
tients, exon 9′, which is spliced into a small proportion
of FALDH transcripts, was sequenced and was found
to be normal.
One Middle Eastern patient carried a missense mu-
tation (1268GrA) in exon 9, along with a single-nucle-
otide sequence variation (1494GrA) 36 bp from the
stop codon in the 3′-UTR of exon 10. No other DNA
changes were found within the coding region of the gene.
We did not have access to other family members for
testing, but the 1494GrA change was not seen in other
patients with SLS or in normal controls. To determine
whether the 1494GrA allele was expressed at the RNA
level, we amplified the FALDH mRNA from the patient’s
fibroblasts by use of RT-PCR. When sequenced, the
1268GrA missense mutation appeared to be homozy-
gous and 1494GrA was not detected. Moreover, the
patient was heterozygous for the 1446A/T polymor-
phism in exon 10 when testing of genomic DNA was
done, but only the 1446A allele was detected in the
mRNA. These results suggest that the transcript origi-
nating from the 1494GrA allele (also containing the
1446T polymorphism) was unstable or was not ex-
pressed. Nevertheless, rigorous proof that the 1494GrA
change causes disease and is not simply linked to another
undetected mutation will require expression studies.
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Table 5
SNP Haplotype Associations with Common FALDH Mutations
SNP HAPLOTYPE ASSOCIATED
WITH SNP POLYMORPHISM
FALDH MUTATION(S)
No. of Probands
with Haplotype
Intron 1
15339
Intron 3
47131
Intron 6
94053
Exon 10
1446
233GrA 2 C T C A
4711delG 1 C/T C/T C/G T
1 C T C/G A/T
551CrT 2 C T G T
1 T C C T
1 C/T C/T C/G T
682CrT 1 C T C A
1 C C C A
1 C C G T
710GrA 2 T C C T
733GrAa 1 T T C A
733GrA, 901GrC, 906delT, 909TrG 2 C T G T
1 C/T C/T C/G T
1 C T C/G A/T
7981delG 1 T T C T
1 T C C T
941–943delCCCins21bp 4 T C C T
943CrT 6 T C C T
1 T C/T C/G T
1 C/T C/T C/G T
1094CrT 2 T C C T
1 T C/T C A/T
1297–1298 delGA 11 T C C T
3 C/T C/T C A/T
1 C/T C/T C/G T
1 C/T C C T
1311–1312insACAAA 1 C T C T
1 C/T C/T C T
a This mutation, seen in a single patient with SLS, is included for comparison with the patients carrying
the 733GrA/901GrC/906delT/909TrG complex allele.
Haplotype Analysis of Common Mutations
Twelve of the mutations were carried by more than
one proband. Many of these mutations were found in
patients from common geographic or ethnic populations
who could share distant ancestors, or the mutations
might have recurred independently. To investigate these
alternate possibilities, we determined, by using the four
SNPs, the FALDH haplotypes of the probands who had
identical mutations (table 5). Four of the mutations were
found on more than one haplotype. Three of these mu-
tations (551CrT, 682CrT, and 733GrA) were asso-
ciated with haplotypes that differed at two or more
SNPs, suggesting that the mutations arose independently
on different genetic backgrounds. Each of these muta-
tions occurs at a CpG dinucleotide. The 551CrT mu-
tation was carried by four European patients, two of
whom had homozygous haplotypes that differed at three
SNPs. The 682CrT mutation was carried by four pa-
tients of Middle Eastern origin and was present on three
different FALDH haplotypes. Interestingly, the patient
who was homozygous for the isolated 733GrA muta-
tion in exon 5 had a haplotype that, at three SNPs,
differed from that of the patients carrying 733GrA in
combination with the complex mutation in exon 6
(901GrC, 906delT, and 909TrG). This suggests that
the complex mutation did not originate on the 733GrA
allele and that this missense mutation originated inde-
pendently on two occasions. One additional mutation
(7981delG) was carried by two patients, one of Eu-
ropean descent and the other of whom was Japanese,
who differed at one SNP. All of the other common mu-
tations were each associated with identical FALDH hap-
lotypes among the probands carrying them, which is
consistent with existence of a shared ancestor.
Discussion
Our results have uncovered a striking mutational het-
erogeneity in SLS. Among 63 probands with SLS, 49
different mutations were found. Forty-two of the mu-
tations are novel, and 7 mutations have been previously
reported. Thirty-seven of the mutations were each car-
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ried by one proband and can be considered private. To
our knowledge, this cohort with SLS represents the ma-
jority of enzymatically confirmed patients identified to
date. With limited clinical information about many of
the patients, we did not attempt genotype-phenotype
correlations.
Previous studies involving linkage analysis of families
of diverse ethnic origins have mapped SLS to chromo-
some 17p11.2 and have found no evidence for locus
heterogeneity (Pigg et al. 1994; Rogers et al. 1995; La-
cour et al. 1996). Our results also support a single SLS
locus, since all of the probands studied here had mu-
tations in the FALDH gene. This is consistent with bi-
ochemical evidence that, except for NAD, the active
FALDH enzyme requires no additional cofactors or pro-
teins for aldehyde oxidative activity (Kelson et al. 1997).
Mutations in the FALDH gene appeared to be ran-
domly distributed. However, four different muta-
tions—including two deletions, a transition, and a trans-
version—involved nucleotides at or around nt 798.
Three of these mutations disrupted normal splicing, and
the remaining missense mutation (798GrC) seemed to
result in an unstable mRNA. The clustering of mutations
at this site may be fortuitous or may reflect ascertain-
ment bias because of a greater susceptibility to functional
impairment. This particular splice-donor site at exon 5
differs from others in the FALDH gene because of its
short palindromic character (gtttg), which may be more
susceptible to mutation.
Deletions and insertions within exons accounted for
30% of all mutations. In most cases in which more than
one nucleotide was deleted or inserted, the mutations
occurred at short palindromic sequences and probably
arose from errors introduced by DNA polymerase dur-
ing replication. In the case of the large, 2.8-kb deletion,
a short duplication was introduced at the 3′ break site
in intron 2, suggesting unequal crossing-over. No com-
plementary sequences or potential hairpin loops that
would explain the error were seen at the deletion
breakpoints.
Twenty-two missense mutations altering 21 amino
acid residues were identified among the patients with
SLS. To establish that these were disease-causing mu-
tations, we expressed 20 of the mutations in mammalian
cells and found that 19 of them resulted in a severe loss
of FALDH enzyme activity. In contrast, the 798GrC
(K266N) missense mutation caused a mild reduction of
enzyme catalytic activity but a more profound decrease
in its mRNA level, which emphasizes the pleiotropic ef-
fects of certain missense mutations that can influence
mRNA splicing and alter transcript stability (Cooper
and Mattox 1997). The 733GrA (D245N) mutation
had previously been thought to be an innocuous poly-
morphism as a result of its association with a second
complex mutation on the same allele in some patients
with SLS (Sille´n et al. 1998). This mutation was the sole
nucleotide alteration in one homozygous patient with
SLS and was clearly destructive to FALDH catalytic ac-
tivity when expressed in mammalian cells.
The mutations leading to amino acid substitutions
should prove useful for providing the structure-function
correlations in FALDH. This enzyme is a member of a
large family of aldehyde dehydrogenase (ALDH) pro-
teins that show varying degrees of sequence homology
(Perozich et al. 1999). Recently, a closely related cyto-
solic class 3 ALDH from rat has been crystallized, and
the three-dimensional structure has been determined
(Liu et al. 1997). When the carboxy-terminal region of
human FALDH that is not present in the rat enzyme is
excluded, the two proteins share 65% amino acid iden-
tity. Eighteen of 21 amino acid positions altered by the
missense mutations in FALDH involve residues shared
with the rat protein. This rat ALDH should provide a
basis for modeling the human FALDH protein and for
determination of the structural alterations caused by the
missense mutations.
The splice-site mutations, which accounted for 18%
of the detected mutations, often caused multiple FALDH
transcript abnormalities. Five of these mutations in-
volved splice-donor sites and resulted in skipping of the
upstream one or two exons, which commonly occurs
with splice-donor mutations (Nakai and Sakamoto
1994; O’Neill et al. 1998). The four mutations involving
splice-acceptor sites caused skipping of either all or a
portion of the downstream one or two exons. Two of
these splice-acceptor-site mutations also caused utiliza-
tion of cryptic acceptor sites. The 4722ArG mutation
resulted in recognition of a downstream cryptic acceptor
site, whereas the 68114TrA mutation had multiple
effects on the mRNA, including exon skipping and util-
ization of an upstream cryptic acceptor site leading to
insertion of intronic sequence into the transcript.
Several common mutations were clustered among
patients of European or Middle Eastern descent, sug-
gesting a founder effect. The mutation most frequently
seen in our probands with SLS was 1297–1298delGA,
which was restricted to patients of European origin.
Among the 37 patients with SLS who were of Euro-
pean descent, 1297–1298delGA was carried by 16
probands, and SNP haplotype analysis, although lack-
ing the statistical power of microsatellite markers, is
consistent with their being distantly related. Nine Eu-
ropean probands carried the 943CrT mutation,
which was previously detected in patients with SLS
who were from northern Europe and Sweden and who
shared a common microsatellite-marker haplotype
(De Laurenzi et al. 1997). Among the European pro-
bands studied here, 54% carried either 943CrT or
1297–1298delGA, and the two mutations accounted
for 36% of all European SLS alleles. Notably, 23 mu-
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tations accounted for the remaining European SLS
alleles. Among patients from the Middle East, 10
different mutations were identified, and 3 of these
(682CrT, 710GrA, and 941–943delCCCins21nt)
were found in more than one kindred.
Haplotype analysis using the SNPs within the FALDH
gene was useful for investigation of the origin of the
common mutations and the genetic relatedness of the
patients carrying them. In this regard, we found that at
least three common mutations (551CrT, 682CrT, and
733GrA), each associated with haplotypes that differ
by two or more SNPs, probably originated indepen-
dently and may represent mutational hotspots. These
mutations occur at CpG dinucleotides and might have
arisen by deamination of a methylated cytosine. How-
ever, the conclusion that these mutations arose on several
occasions must be tempered by the contradictory finding
that the 551CrT and 682CrT mutations were restricted
to European and Middle Eastern patients, respectively.
This geographic clustering is not consistent with recur-
rent mutations, which should arise independent of ge-
ographic region, and argues that these two FALDH mu-
tations represent ancestral SLS alleles upon which the
different SNP haplotypes arose from rare intragenic re-
combination. If the haplotypes were products of intra-
genic recombination, both mutations would require two
crossover events to account for the haplotype diversity
seen. If it is assumed that 1 Mb is equivalent to a map
distance of 1 cM and that the mutations were 4–6 kb
away from the flanking SNPs, intragenic recombination
between the mutation and one SNP would be expected
to occur with a frequency of ∼5# 105. The likelihood
of two crossover events occurring within the gene (25
# 1010) is lower than the estimated transition-mutation
rate at CpG dinucleotides (368 # 10-10/bp/germ cell)
(Koeberl et al. 1990), which supports the notion that
551CrT and 682CrT are recurrent mutations. If so,
the geographic clustering of the two mutations may be
fortuitous. A fourth mutation (7981delG) was asso-
ciated with two haplotypes that differed by one SNP
only; however, this mutation was detected in two pa-
tients—one of European descent and the other from Ja-
pan—who are unlikely to share common ancestors.
Identification of additional SNPs within the FALDH
gene should improve the power of haplotype analysis
for detection of recurrent mutations.
Our studies provide a foundation for the development
of DNA-based methods for the diagnosis of SLS. Since
the majority of the FALDH mutations are private and
are scattered throughout the gene, with the use of current
techniques the DNA-based diagnosis of SLS will be a
challenge. Screening methods have been developed for
the two common European mutations, by use of either
restriction-enzyme digestion of PCR amplicons (De Lau-
renzi et al. 1997; Sille´n et al. 1997) or allele-specific PCR
(Rizzo et al. 1997), and similar approaches could be
taken for the common Middle Eastern mutations. How-
ever, until newer and less costly molecular methods are
developed for mutation screening, perhaps on the basis
of DNA chip technology, the diagnosis of SLS will prob-
ably still depend on enzymatic assays of FALDH activity.
In contrast to diagnostic screening, identification of the
specific mutations segregating in kindreds will prove in-
valuable for carrier detection, prenatal diagnosis, and
genotype-phenotype correlations in SLS.
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